GENE ONLINE|News &
From Billions to Bedside: Who Is Actually Building the Anti-Aging Pipeline
The global longevity economy is projected to exceed US$27 trillion annually by 2050, driven by population aging and demand for healthier lifespan extension. Image: Shutterstock
Billions of dollars have poured into companies promising to treat aging as a disease. A handful of them have moved from thesis to clinic, and the gap between the two groups is widening. Longevity biotech stopped being a fringe pursuit somewhere between Altos Labs’ record-setting launch and the first patient dosed with a cellular rejuvenation … From Billions to Bedside: Who Is Actually Building the Anti-Aging Pipeline Read More » This post is only available to members.
It's free! Log in now to read
LATEST
EVENT
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
